Combined subcutaneous implantable cardioverter defibrillator and pacemaker devices in complex congenital heart disease: a single-center experienced based study.
Congenital heart disease
Pacemaker
Subcutaneous implantable cardioverter defibrillator
Sudden death
Transvenous implantable cardioverter defibrillator
Ventricular arrhythmias
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
04
06
2023
accepted:
11
10
2023
medline:
25
10
2023
pubmed:
25
10
2023
entrez:
25
10
2023
Statut:
aheadofprint
Résumé
Subcutaneous implantable cardioverter defibrillators (S-ICD) are widely accepted therapy in congenital heart disease (CHD) patients at risk of life-threatening ventricular arrhythmias or sudden cardiac death (SCD) when pacing is not required. Occasionally, pacemaker (PM)-dependent CHD patients will subsequently develop an indication for a cardioverter defibrillator. The use of S-ICD in complex CHD patients who have had already PM devices implanted implies some specific considerations, as the safety for these patients in unknown and recommendations among physicians may vary widely. We review the data and studied the indications for S-ICD in complex CHD with previous PM and discuss its usefulness in clinical practice. From a large cohort of 345 patients enrolled in the S-ICD Monaldi care registry, which encompass all the patients implanted in the Monaldi Hospital of Naples, we considered 11 consecutive complex CHD patients (10M/1F aged 40.4 ±18.4 years) who underwent S-ICD implant after a previous PM implant, from February 2015 to October 2022. Mean follow-up was 25.5 ± 22 months. All the patients showed a good compliance to the device system with no complications (infections or skin erosions). In complex CHD with already implanted PM devices, S-ICD implant appears to be a safe alternative to PM upgrading to transvenous ICD system, avoiding abandoned leads or life-threatening lead extraction. However, there are important issues with regard to testing and programming that need to be addressed at the time of implantation.
Sections du résumé
BACKGROUND
BACKGROUND
Subcutaneous implantable cardioverter defibrillators (S-ICD) are widely accepted therapy in congenital heart disease (CHD) patients at risk of life-threatening ventricular arrhythmias or sudden cardiac death (SCD) when pacing is not required. Occasionally, pacemaker (PM)-dependent CHD patients will subsequently develop an indication for a cardioverter defibrillator. The use of S-ICD in complex CHD patients who have had already PM devices implanted implies some specific considerations, as the safety for these patients in unknown and recommendations among physicians may vary widely.
METHODS
METHODS
We review the data and studied the indications for S-ICD in complex CHD with previous PM and discuss its usefulness in clinical practice.
RESULTS
RESULTS
From a large cohort of 345 patients enrolled in the S-ICD Monaldi care registry, which encompass all the patients implanted in the Monaldi Hospital of Naples, we considered 11 consecutive complex CHD patients (10M/1F aged 40.4 ±18.4 years) who underwent S-ICD implant after a previous PM implant, from February 2015 to October 2022. Mean follow-up was 25.5 ± 22 months. All the patients showed a good compliance to the device system with no complications (infections or skin erosions).
CONCLUSIONS
CONCLUSIONS
In complex CHD with already implanted PM devices, S-ICD implant appears to be a safe alternative to PM upgrading to transvenous ICD system, avoiding abandoned leads or life-threatening lead extraction. However, there are important issues with regard to testing and programming that need to be addressed at the time of implantation.
Identifiants
pubmed: 37878161
doi: 10.1007/s10840-023-01670-1
pii: 10.1007/s10840-023-01670-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, Lung B, Kluin J, Lang IM, Meijboo F, Moons P, Mulder BJM, Oechslin E, Roos-Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K, ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563–645.
doi: 10.1093/eurheartj/ehaa554
pubmed: 32860028
Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmia in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm. 2014;11(10):e102–65.
doi: 10.1016/j.hrthm.2014.05.009
pubmed: 24814377
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15(10):e73–e189.
doi: 10.1016/j.hrthm.2017.10.036
pubmed: 29097319
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. ESC Scientific Document Group. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867.
doi: 10.1093/eurheartj/ehv316
pubmed: 26320108
Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(12):1494–563.
doi: 10.1016/j.jacc.2018.08.1028
pubmed: 30121240
Peters B, Will A, Berger F, Butter C. Implantation of a fully subcutaneous ICD in a patient with single ventricle morphology and Eisenmenger physiology. Acta Cardiol. 2012;67:473–5.
doi: 10.1080/AC.67.4.2170692
pubmed: 22998005
Zeb M, Curzen N, Veldtman G, et al. Potential eligibility of congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator based on surface electrocardiogram mapping. Europace. 2015;17:1059–67.
doi: 10.1093/europace/euu375
pubmed: 25678600
Vehmeijer JT, Brouwer TF, Limpens J, et al. Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis. Eur Heart J. 2016;37:1439–48.
doi: 10.1093/eurheartj/ehv735
pubmed: 26873095
pmcid: 4914887
Moore JP, Mondesert B, Lloyd MS, et al. Clinical experience with the subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease. Circ Arrhythm Electrophysiol. 2016;9:e004338.
doi: 10.1161/CIRCEP.116.004338
pubmed: 27635073
Silvetti MS, Pazzano V, Verticelli L, et al. Subcutaneous implantable cardioverter-defibrillator: is it ready for use in children and young adults ?. A single-centre study. Europace. 2018;20(12):1966–73.
doi: 10.1093/europace/euy139
pubmed: 29939256
Sarubbi B, Correra A, Colonna D, et al. Subcutaneous implantable cardioverter defibrillator in complex adult congenital heart disease. Results from the S-ICD “Monaldi Care” registry. Int Journal of Cardiol CHD. 2021;3:100091. https://doi.org/10.1016/j.ijcchd.2021.100091 .
doi: 10.1016/j.ijcchd.2021.100091
Sarubbi B, Colonna D, Correra A, et al. Subcutaneous implantable cardioverter defibrillator in children and adolescents: results from the S-ICD “Monaldi care” registry. J Interv Card Electrophysiol. 2022;63(2):283–93. https://doi.org/10.1007/s10840-021-00966-4 .
doi: 10.1007/s10840-021-00966-4
pubmed: 33709295
D’Onofrio A, Pieragnoli P, Biffi M, et al. Subcutaneous implantable cardioverter defibrillator implantation: an analysis of Italian practice and its evolution. Int J Cardiol. 2018;272:162–7.
doi: 10.1016/j.ijcard.2018.07.139
pubmed: 30087041
Droghetti A, Basso RE, Scimia P, Harizai F, Marini M. Ultrasound-guided serratus anterior plane block combined with the two-incision technique for subcutaneous ICD implantation. Pacing Clin Electrophysiol. 2018;41(5):517–23.
doi: 10.1111/pace.13318
pubmed: 29493802
Knops RE, Olde Nordkamp LR, de Groot JR, Wilde AA. Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2013;10:1240–3.
doi: 10.1016/j.hrthm.2013.05.016
pubmed: 23707489
Bianchi V, Bisignani G, Migliore F, et al. “S-ICD rhythm detect” investigators. Safety of omitting defibrillation efficacy testing with subcutaneous defibrillators: a propensity-matched case-control study. Circ Arrhythm Electrophysiol. 2021;14(12):e010381. https://doi.org/10.1161/CIRCEP.121.010381 .
doi: 10.1161/CIRCEP.121.010381
pubmed: 34852635
Payne JE, Badertscher P, Field ME, Sturdivant JL, Gold MR. Relationship of shock energy to impedance during subcutaneous implantable cardioverter-defibrillator testing. Circ Arrhythm Electrophysiol. 2020;13:e008631.
doi: 10.1161/CIRCEP.120.008631
pubmed: 32703008
Quast A-FBE, Baalman SWE, Brouwer TF, et al. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable defibrillator: the PRAETORIAN score. Heart Rhythm. 2019;16:403–10.
doi: 10.1016/j.hrthm.2018.09.029
pubmed: 30292861
Lee JC, Epstein LM, Huffer LL, Stevenson WG, Koplan BA, Tedrow UB. ICD lead pro-arrhythmia cured by lead extraction. Heart Rhythm. 2009;6(5):613–8.
doi: 10.1016/j.hrthm.2009.01.039
pubmed: 19328039
Lin G, Nishimura RA, Connolly HM, Dearani JA, Sundt TM 3rd, Hayes DL. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. J Am Coll Cardiol. 2005;45(10):1672–5.
doi: 10.1016/j.jacc.2005.02.037
pubmed: 15893186
Willy K, Reinke F, Bogeholz N, et al. The entirely subcutaneous ICD system in patients with congenital heart disease: experience from a large single-centre analysis. Europace. 2019;21:1537–42.
doi: 10.1093/europace/euz190
pubmed: 31302706
Bettin M, Larbig R, Rath B, et al. Long-term experience with the subcutaneous implantable cardioverter-defibrillator in teenagers and young adults. J Am Coll Cardiol EP. 2017;3:1499–506.
Porterfield C, DiMarco JP, Mason PK. Effectiveness of implantation of a subcutaneous implantable cardioverter-defibrillator in a patient with complete heart block and a pacemaker. Am J Cardiol. 2015;115(2):276–8.
doi: 10.1016/j.amjcard.2014.10.036
pubmed: 25465940
Kuschyk J, Stach K, Tülümen E, et al. Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices. Heart Rhythm. 2015;12(11):2230–8.
doi: 10.1016/j.hrthm.2015.06.022
pubmed: 26073595
Steinberg C, Chakrabarti S, Krahn AD, Bashir J. Nothing inside the heart - combining epicardial pacing with the S-ICD. Heart Rhythm Case Rep. 2015;1(6):419–23.
Huang J, Patton KK, Prutkin JM. Concomitant use of the subcutaneous implantable cardioverter defibrillator and a permanent pacemaker. Pacing Clin Electrophysiol. 2016;39(11):1240–5.
doi: 10.1111/pace.12955
pubmed: 27734502
Gemein C, Haj M, Schmitt J. Combining a subcutaneous ICD and a pacemaker with abdominal device location and bipolar epicardial left ventricular lead: first-in-man approach. Europace. 2016;18(8):1279.
doi: 10.1093/europace/euv443
pubmed: 26843577
Tjong FV, Brouwer TF, Smeding L, et al. Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance. Europace. 2016;18(11):1740–7.
doi: 10.1093/europace/euv457
pubmed: 26941338
Ip JE, Wu MS, Kennel PJ, et al. Eligibility of pacemaker patients for subcutaneous implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 2017;28(5):544–8.
doi: 10.1111/jce.13182
pubmed: 28185354
Lüker J, Sultan A, Sreeram N, Brockmeier K, Steven D. Implantation of a subcutaneous implantable cardioverter defibrillator with right parasternal electrode position in a patient with D-transposition of the great arteries and concomitant AAI pacemaker: a case report. Eur Heart J Case Rep. 2018;2(3):yty099.
pubmed: 31020176
pmcid: 6177110
Baroni M, Colombo G, Testoni A, et al. Combined leadless pacemaker and subcutaneous implantable cardioverter-defibrillator to manage recurrent transvenous system failures. J Electrocardiol. 2019;54:43–6.
doi: 10.1016/j.jelectrocard.2019.03.002
pubmed: 30870634
Abbott N, Bender A, Henrikson C, et al. Adverse device-device interaction between pacemaker and subcutaneous implantable cardiac defibrillator. Pacing Clin Electrophysiol. 2021;44(11):1944–8.
doi: 10.1111/pace.14325
pubmed: 34296775
Lambiase PD, Barr C, Theuns DAMJ, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35:1657–65.
doi: 10.1093/eurheartj/ehu112
pubmed: 24670710
pmcid: 4076663
Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS Registry. J Am Coll Cardiol. 2015;65:1605–15.
doi: 10.1016/j.jacc.2015.02.047
pubmed: 25908064
Healey JS, Hohnloser SH, Glikson M, et al. Shockless IMPLant Evaluation [SIMPLE] investigators. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non- inferiority, randomised controlled trial (SIMPLE). Lancet. 2015;385:785–91.
doi: 10.1016/S0140-6736(14)61903-6
pubmed: 25715991